{"id":"atg-mycoph-nolate-mof-til-tacrolimus","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Bone marrow suppression"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATG (antithymocyte globulin) depletes T lymphocytes; tacrolimus inhibits calcineurin to block T-cell activation and cytokine production; mycophenolate mofetil inhibits inosine monophosphate dehydrogenase to suppress B and T lymphocyte proliferation. Together, these agents provide synergistic immunosuppression for transplant rejection prevention.","oneSentence":"This combination suppresses the immune system through multiple pathways to prevent organ rejection after transplantation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:24.327Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute organ rejection in solid organ transplantation"},{"name":"Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation"}]},"trialDetails":[{"nctId":"NCT00538265","phase":"PHASE4","title":"Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2005-05","conditions":"Liver Transplantation","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":131,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mycophénolate mofétil = Cellcept"],"phase":"marketed","status":"active","brandName":"ATG+mycophénolate mofétil+tacrolimus","genericName":"ATG+mycophénolate mofétil+tacrolimus","companyName":"University Hospital, Toulouse","companyId":"university-hospital-toulouse","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation. Used for Prevention of acute organ rejection in solid organ transplantation, Graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}